Sponsored by AstraZeneca and Daiichi Sankyo
This activity is not certified for credit.
Thursday, September 6
The program objective is to gain in-depth knowledge of MOVANTIK, the first once-daily, oral therapy in its class specifically designed for the treatment of OIC in adult patients with chronic non-cancer pain.
Gerard DeGregoris III, MD
Posted on August 24, 2018